BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) CMO William P. Sheridan sold 64,310 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ BCRX) traded down $0.04 during mid-day trading on Wednesday, reaching $4.72. The company had a trading volume of 509,200 shares, compared to its average volume of 1,569,897. BioCryst Pharmaceuticals, Inc. has a 1-year low of $3.95 and a 1-year high of $9.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). The firm had revenue of $8.76 million during the quarter, compared to analyst estimates of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period last year, the company posted ($0.16) EPS. equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

WARNING: “William P. Sheridan Sells 64,310 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) Stock” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/15/william-p-sheridan-sells-64310-shares-of-biocryst-pharmaceuticals-inc-bcrx-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of BCRX. Legal & General Group Plc boosted its stake in BioCryst Pharmaceuticals by 4.9% during the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 860 shares in the last quarter. Principal Financial Group Inc. boosted its stake in BioCryst Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 45 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $126,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at $132,000. Finally, SG Americas Securities LLC lifted its position in shares of BioCryst Pharmaceuticals by 98.6% during the 3rd quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 13,402 shares during the last quarter. 71.30% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have issued reports on BCRX. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 8th. Royal Bank Of Canada initiated coverage on BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a “sector perform” rating and a $6.00 price objective on the stock. J P Morgan Chase & Co upped their target price on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a report on Wednesday, September 6th. Jefferies Group LLC raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $5.00 to $7.00 in a report on Wednesday, September 6th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $15.00 target price (up from $13.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. BioCryst Pharmaceuticals has a consensus rating of “Hold” and an average price target of $9.13.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.